Transcend Therapeutics
Jennifer brings over 25 years of neuroscience research experience from MIT (B.S.), Yale (Ph.D.) and the Rockefeller University (post-doctoral fellowship), where she worked closely with Ron Duman - who proposed the neurotrophic hypothesis of antidepressant activity- and Nobel Laureate Paul Greengard, studying neuropsychiatric diseases at molecular, cellular and behavioral levels. Prior to joining Transcend, Jennifer was the Director of R&D at Magnolia Neurosciences.
Transcend Therapeutics
1 followers
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.